These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38852799)

  • 1. Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions.
    Somabattini RA; Sherin S; Siva B; Chowdhury N; Nanjappan SK
    Life Sci; 2024 Aug; 351():122806. PubMed ID: 38852799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
    Fishman J; Kim Y; Parisé H; Bercaw E; Smith Z
    J Med Econ; 2024; 27(1):1108-1118. PubMed ID: 39155764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; White LA; Graf TN; Oberlies NH; Clarke JD
    Drug Metab Dispos; 2024 Apr; 52(5):355-367. PubMed ID: 38485280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Hardwick RN; Cherrington NJ
    Liver Int; 2017 Jul; 37(7):1074-1081. PubMed ID: 28097795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Karim G; Bansal MB
    touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.
    Cho SJ; Kim SB; Cho HJ; Chong S; Chung SJ; Kang IM; Lee JI; Yoon IS; Kim DD
    J Agric Food Chem; 2016 Jul; 64(27):5598-606. PubMed ID: 27321734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice.
    Li H; Clarke JD; Dzierlenga AL; Bear J; Goedken MJ; Cherrington NJ
    J Biochem Mol Toxicol; 2017 Feb; 31(2):. PubMed ID: 27712037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
    Guirguis E; Dougherty J; Thornby K; Grace Y; Mack K
    Ann Pharmacother; 2024 Jun; ():10600280241259528. PubMed ID: 38887011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coleus forskohlii Extract Attenuated the Beneficial Effect of Diet-Treatment on NASH in Mouse Model.
    Suzuki S; Nishijima C; Sato Y; Umegaki K; Murata M; Chiba T
    J Nutr Sci Vitaminol (Tokyo); 2020; 66(2):191-199. PubMed ID: 32350181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
    Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
    Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
    Marie S; Frost KL; Hau RK; Martinez-Guerrero L; Izu JM; Myers CM; Wright SH; Cherrington NJ
    Acta Pharm Sin B; 2023 Jan; 13(1):1-28. PubMed ID: 36815037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver.
    Rey-Bedon C; Banik P; Gokaltun A; Hofheinz O; Yarmush ML; Uygun MK; Usta OB
    Biomed Pharmacother; 2022 Feb; 146():112377. PubMed ID: 35062050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.
    Cobbina E; Akhlaghi F
    Drug Metab Rev; 2017 May; 49(2):197-211. PubMed ID: 28303724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.